Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Enzalutamide Plus Abiraterone Acetate and Prednisolone Not Recommended for mHSPC

September 11, 2022
By Hayley Virgil
Article
Conference|European Society for Medical Oncology Congress (ESMO)

Despite the combination of enzalutamide plus abiraterone acetate and prednisolone (AAP) falling short in patients with metastatic hormone-sensitive prostate cancer, although androgen deprivation therapy plus AAP resulted in a clinically meaningful overall survival benefit.

Although treatment with androgen deprivation therapy (ADT) plus abiraterone acetate (Zytiga) and prednisolone (AAP) resulted in a long-lasting clinically meaningful overall (OS) benefit in patients with metastatic hormone-sensitive prostate cancer (mHSPC), treatment of AAP plus enzalutamide (Xtandi) could not be recommended, according to results from a combined analysis of phase 3 trials from the STAMPEDE platform protocol (NCT00268476), presented at the 2022 European Society for Medical Oncology Congress.1

In 1 trial focused on AAP, investigators reported a total of 293 OS events for patients treated with ADT and AAP plus 371 events for patients treated with ADT alone (HR, 0.62; 95% CI, 0.53-0.73; P = 1.6x10-9). In a trial focused on AAP plus enzalutamide, investigators observed a total of 228 events among patients who were treated with ADT, AAP, and enzalutamide, and 292 events for patients treated with ADT (HR, 0.65; 95% CI, 0.55-0.77; P = 1.4x10-6; interaction HR, 1.05; 95% CI, 0.83-1.32; P = 0.71; between-trial heterogeneity, I2 P = 0.7).

In terms of other survival outcomes, OS at 84 months among patients treated with ADT was 30% (95% CI, 26%-34%) compared with 48% (95% CI, 43%-52%) in those treated with ADT plus AAP. Moreover, the restricted mean survival time was 50.4 months and 60.6 months in each respective arm (P = 6.6x10-9).

“This is clear and significant evidence of an improvement in survival in both trials was as you would expect for the abiraterone trial,” Gerhardt Attard, MD, PhD, FRCP, a clinician scientist, team leader, honorary medical oncology consultant, and John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. “But we see no evidence of difference in treatment effect between the 2 trials, and there is no evidence between trial heterogeneity.”

The population included in the STAMPEDE platform protocol featured patients with M1 mHSPC with 1 or more bone metastases and CT scan of the pelvis, abdomen, and chest, as well as patients with M0, high-risk, localized disease that is node-positive, node-negative with 2 or more high-risk features, or relapsed with high-risk features. To be eligible for the analysis, patients were required to have histologically confirmed prostate adenocarcinoma and adequate organ function but were excluded if they had confirmed clinically significant cardiovascular disease.

In the AAP trial, a total of 502 patients were treated with standard of care (SOC) ADT plus or minus docetaxel and 501 patients received SOC and AAP.2 In the AAP plus enzalutamide trial, a total of 454 patients were treated with SOC compared with 462 patients who received SOC, AAP, and enzalutamide.3 The trials could not have overlapping controls and were required to have the same protocol and eligibility criteria. The primary outcome measure was OS. Investigators reported that the goal of the analysis was to assess the impact of AAP plus enzalutamide compared with AAP and other enzalutamide trials.

Follow-up for the study was based on available funding. The trials stopped further trial data collection on November 30, 2021, with a final data freeze on July 3, 2022.

All groups were randomized and well balanced. The median patient age was 68 years (range, 63-72) with a median prostate-specific antigen before ADT of 96 ng/mL. Moreover, 94% of patients had de novo disease and 6% had relapsed following radical treatment. The AAP study had a median follow-up of 95.8 months compared with 71.7 months in the AAP plus enzalutamide trial. At the end of the trials, 117 of 498 patients in the AAP and enzalutamide trial were still being treated with AAP, 98 were still being treated with AAPand enzalutamide, 3 were still on enzalutamide, and 10 were still on AAP.

In a prespecified subgroup analysis based on stratification factors, Attard described an interaction based on age and regular non-steroidal anti-inflammatory drug and/or aspirin use within the AAP trial. The correlation was not observed in the enzalutamide trial. The subgroup analysis also assessed docetaxel use in patients who received SOC and SOC plus AAP and enzalutamide.

“This was a late amendment to our protocol. Nine percent of patients or about 148 were randomized in the AAP and enzalutamide trial,” according to Attard. “Physicians were given the option to decide whether to offer docetaxel and as you would expect, those patients who were planned [to receive] docetaxel were younger, had a higher Gleason sum, and were more likely to have pain from prostate cancer. Overall, the number is very small.”

In terms of metastatic progression-free survival, the HR was 0.50 (95% CI, 0.43-0.58) in the AAP trial compared with 0.52 (95% CI, 0.44-0.62) in the AAP plus enzalutamide trial. There was no evidence of a difference in treatment effect or between-trial heterogeneity.

In terms of safety, toxicity was similar between arms, although adverse effects (AEs) occurred more frequently in the AAP plus enzalutamide arm. Compared with SOC, common AEs associated with the experimental treatments were fatigue, liver function derangement, and hypertension. The most significant grade 5 AEs were respiratory in the AAP trial and cardiac in the AAP plus enzalutamide trial.

References

  1. Attard G, Murphy L, Clarke N, et al. Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol. Ann Oncol. 2022;33(suppl 7):LBA62. doi:10.1016/annonc/annonc1089
  2. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235-1248. doi:10.1093/annonc/mdy072
  3. Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.